A New Sense, “Ninja Experience” Fusing the Real and the Virtual World.“VR NINJA DOJO” Entertaining Adults and Children Has Appeared!
6.3.2019 07:58:00 EET | Business Wire | Press release
Five for Co., Ltd. (Location: Chiyoda-ku Ward, Tokyo, Representative Director: Takayoshi Tanigawa) will open a VR experience entertainment facility, “VR NINJA DOJO” which provides Ninja experience for foreigners visiting Japan on Monday, March 18th, 2019 in Uchikanda, Chiyoda-ku, Tokyo.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190305006076/en/
Interior view of VR NINJA DOJO (Photo: Business Wire)
VR NINJA DOJO is an entertainment facility that provides “Ninja Experience” fusing the real and virtual world for foreigners visiting Japan. One of Japanese cultures, “Ninja”, is also literally popular as “Ninja” overseas. The facility is designed with the stylistic beauty inherent in Japan and is a space where you can feel the unique perspective of the Japan world. Also, this facility is designed with our own technology so that the third parties who do not wear a head-mount display can enjoy the virtual world as well. So, you can unite and enjoy the experience even when your group consists of two or more people. Furthermore, since we explain the operation completely in English, foreigners visiting Japan comfortably use the facility. Visitors will take the full proficiency examination to be a Ninja master through the VR experience after they had realistic discipline and training by doing physical activities.
Recently, the number of foreign visitors has been on the rise in Japan. According to Japan National Tourism Organization (JNTO), the total number of foreign visitors to Japan in 2018 exceeded 30,010,000, which is the first time ever recorded over 30 million people and is an increase of 8.7% from the previous year. It is expected that the number of foreign visitors to Japan will further increase by 2020, but there is some change in their consumption behavior. In the past, "entity-oriented consumption" such as purchasing large quantities of home appliances and cosmetics etc. was mainstream. But, as the EC industry has expanded, there is less value in traveling some places in order to purchase goods there. Instead, "situation-oriented consumption" such as taking experience type services including hot spring tours and kimono experiences is on the increase. The new facility in anticipation of the growing inbound demand provides a new entertainment that will definitely become popular among foreign visitors to Japan.
VR NINJA DOJO provides a Ninja experience, which is only available here, with the concept of “The Hospitality of Japanese Culture in both the 'real' and the 'virtual' world."
|
[Contents of the Experience] |
| The required time for a Ninja Experience is from 75 minutes to 90 minutes, and up to 10 persons in one group can participate. |
| Ninja cosplay experience |
| - Ninja discipline and training in the real and the virtual world |
| - Full proficiency examination (VR experience) |
| - VR ceremonial photograph |
| - Presentation of handscroll type certificate |
|
[Details of the Facility] |
||
|
The Name of the Facility: |
VR NINJA DOJO |
|
|
Opening Date: |
March 18th, 2019 |
|
|
Location of the Facility: |
Takebashi Bldg. 1F, 2-15-15 Uchikanda, Chiyoda-ku, |
|
| Tokyo 101-0047 | ||
|
Eligible Person for the Experience: Foreign residents and tourists in Japan |
||
|
- One accompanying Japanese person per a foreigner is free of charge. |
||
| (Ninja costume and the handscroll type certificate are not included.) | ||
|
- There is a special plan available catering to Japanese only. |
||
|
Official Site: |
||
|
[Company Profile] |
||
|
Company Name: |
Five for Co., Ltd. |
|
|
Date of Establishment: |
March 14th, 2017 |
|
|
Representative Director: |
Takayoshi Tanigawa |
|
|
Location: |
Uchikanda Chuo Bldg. 7F, 1-18-13 Uchikanda, |
|
| Chiyoda-ku, Tokyo 101-0047 | ||
|
Business Description: |
VR Entertainment Content Produce & Development |
|
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190305006076/en/
Contact information
VR NINJA DOJO PR SBY Co., Ltd. Inada / Arai
(Antil Co., Ltd.
Akazaki Ichika / Sato Katsuhiko / Yoshida Yusei)
TEL: (+81)
3-5572-6061
FAX: (+81) 3-6685-5267
E-mail: vr_ninjadojo@vectorinc.co.jp
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 13:38:00 EEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 12:48:00 EEST | Press release
Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom